Elanco Animal Health posted a double-digit gain in 2025, with rising protein demand and its pet-health portfolio driving the performance, according to Investor's Business Daily's review of the company's year.

The headline number matters for veterinary practices because Elanco's results track two forces clinicians see daily: livestock producers expanding output to meet global protein demand, and pet owners sustaining spending on companion-animal health products. Both dynamics shaped the animal-health sector throughout 2025.

Why protein demand lifted the livestock side

Global appetite for meat and protein continued to support the food-animal segment of Elanco's business. When producers scale up herds and flocks, they invest in parasiticides, vaccines and nutritional products — the categories Elanco sells into cattle, poultry and swine operations.

For food-animal practitioners, that commercial strength typically translates into sustained demand for herd-health consulting, vaccination protocols and production-medicine services. Elanco's double-digit result signals that producers kept spending through 2025 rather than pulling back.

What the pet-health side shows

The companion-animal half of the story reflects the durability of pet-care spending. Elanco's pet portfolio — spanning parasiticides and therapeutics for dogs and cats — benefited as owners continued treating pets as household members whose care is non-negotiable, even in a pressured consumer economy.

For small-animal clinics, the takeaway is straightforward: pharmaceutical and parasiticide revenue from major manufacturers remained resilient in 2025, and product supply from one of the industry's largest players stayed aligned with clinic demand.

What Elanco's year means for the sector

Elanco ranks among the largest animal-health companies globally, competing alongside Zoetis, Boehringer Ingelheim and Merck Animal Health. A double-digit year for a company of that scale suggests broad momentum across the animal-health market rather than an isolated product win.

Industry analysts have tracked 2025 as a year in which both the food-animal and companion-animal segments contributed to manufacturer growth — a divergence from earlier cycles when one side offset weakness in the other.

What does this change at the practice level?

For practitioners, manufacturer financial health is a downstream indicator. Strong food-animal revenue points to producers who can pay for veterinary services and preventive programs. Strong pet-product revenue indicates consumers who keep filling prescriptions and purchasing preventives.

Neither implies automatic gains for clinics. But it does suggest the product pipelines, rebate programs and inventory supply that practices depend on remain well funded heading into the next planning cycle.

Investor's Business Daily framed the year as proof that protein and pets — the two pillars of animal health — delivered simultaneously for Elanco in 2025. Whether that dual momentum holds into 2026 will depend on protein prices, consumer pet spending and the pace of new product approvals across the sector.